Targeted gene sequencing and transcriptome sequencing reveal characteristics of NUP98 rearrangement in pediatric acute myeloid leukemia.


Journal

European journal of medical research
ISSN: 2047-783X
Titre abrégé: Eur J Med Res
Pays: England
ID NLM: 9517857

Informations de publication

Date de publication:
02 Sep 2024
Historique:
received: 13 03 2024
accepted: 23 08 2024
medline: 3 9 2024
pubmed: 3 9 2024
entrez: 2 9 2024
Statut: epublish

Résumé

NUP98 rearrangements (NUP98-r) are rare but overrepresented mutations in pediatric acute myeloid leukemia (AML) patients. NUP98-r is often associated with chemotherapy resistance and a particularly poor prognosis. Therefore, characterizing pediatric AML with NUP98-r to identify aberrations is critically important. Here, we retrospectively analyzed the clinicopathological features, genomic and transcriptomic landscapes, treatments, and outcomes of pediatric patients with AML. Nine patients with NUP98-r mutations were identified in our cohort of 142 patients. Ten mutated genes were detected in patients with NUP98-r. The frequency of FLT3-ITD mutations differed significantly between the groups harboring NUP98-r and those without NUP98-r (P = 0.035). Unsupervised hierarchical clustering via RNA sequencing data from 21 AML patients revealed that NUP98-r samples clustered together, strongly suggesting a distinct subtype. Compared with that in the non-NUP98-r fusion and no fusion groups, CMAHP expression was significantly upregulated in the NUP98-r samples (P < 0.001 and P = 0.001, respectively). Multivariate Cox regression analyses demonstrated that patients harboring NUP98-r (P < 0.001) and WT1 mutations (P = 0.030) had worse relapse-free survival, and patients harboring NUP98-r (P < 0.008) presented lower overall survival. These investigations contribute to the understanding of the molecular characteristics, risk stratification, and prognostic evaluation of pediatric AML patients.

Sections du résumé

BACKGROUND BACKGROUND
NUP98 rearrangements (NUP98-r) are rare but overrepresented mutations in pediatric acute myeloid leukemia (AML) patients. NUP98-r is often associated with chemotherapy resistance and a particularly poor prognosis. Therefore, characterizing pediatric AML with NUP98-r to identify aberrations is critically important.
METHODS METHODS
Here, we retrospectively analyzed the clinicopathological features, genomic and transcriptomic landscapes, treatments, and outcomes of pediatric patients with AML.
RESULTS RESULTS
Nine patients with NUP98-r mutations were identified in our cohort of 142 patients. Ten mutated genes were detected in patients with NUP98-r. The frequency of FLT3-ITD mutations differed significantly between the groups harboring NUP98-r and those without NUP98-r (P = 0.035). Unsupervised hierarchical clustering via RNA sequencing data from 21 AML patients revealed that NUP98-r samples clustered together, strongly suggesting a distinct subtype. Compared with that in the non-NUP98-r fusion and no fusion groups, CMAHP expression was significantly upregulated in the NUP98-r samples (P < 0.001 and P = 0.001, respectively). Multivariate Cox regression analyses demonstrated that patients harboring NUP98-r (P < 0.001) and WT1 mutations (P = 0.030) had worse relapse-free survival, and patients harboring NUP98-r (P < 0.008) presented lower overall survival.
CONCLUSIONS CONCLUSIONS
These investigations contribute to the understanding of the molecular characteristics, risk stratification, and prognostic evaluation of pediatric AML patients.

Identifiants

pubmed: 39223643
doi: 10.1186/s40001-024-02042-9
pii: 10.1186/s40001-024-02042-9
doi:

Substances chimiques

Nuclear Pore Complex Proteins 0
Nup98 protein, human 0
nuclear pore complex protein 98 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

448

Subventions

Organisme : Pediatric Leukemia Diagnosis and Therapeutic Technology Research Center of Zhejiang Province
ID : JBZX-201904
Organisme : Zhejiang University Special Funds Project of Fundamental Research Funds
ID : 226-2022-00021
Organisme : Natural Science Foundation of Zhejiang Province, China
ID : LY19H190005

Informations de copyright

© 2024. The Author(s).

Références

Bolouri H, Farrar JE, Triche T Jr, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24(1):103–12.
doi: 10.1038/nm.4439 pubmed: 29227476
Struski S, Lagarde S, Bories P, et al. NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis. Leukemia. 2017;31(3):565–72.
doi: 10.1038/leu.2016.267 pubmed: 27694926
Michmerhuizen NL, Klco JM, Mullighan CG. Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies. Blood. 2020;136(20):2275–89.
doi: 10.1182/blood.2020007093 pubmed: 32766874 pmcid: 7702474
Iacobucci I, Wen J, Meggendorfer M, et al. Genomic subtyping and therapeutic targeting of acute erythroleukemia. Nat Genet. 2019;51(4):694–704.
doi: 10.1038/s41588-019-0375-1 pubmed: 30926971 pmcid: 6828160
Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood. 2011;118(13):3645–56.
doi: 10.1182/blood-2011-04-346643 pubmed: 21813447
Noort S, Wander P, Alonzo TA, et al. The clinical and biological characteristics of NUP98-KDM5A in pediatric acute myeloid leukemia. Haematologica. 2021;106(2):630–4.
doi: 10.3324/haematol.2019.236745 pubmed: 32381579
Miyamura T, Moritake H, Nakayama H, et al. Clinical and biological features of paediatric acute myeloid leukaemia (AML) with primary induction failure in the Japanese paediatric leukaemia/lymphoma study group AML-05 study. Br J Haematol. 2019;185(2):284–8.
doi: 10.1111/bjh.15799 pubmed: 30784060
Laurell E, Beck K, Krupina K, et al. Phosphorylation of Nup98 by multiple kinases is crucial for NPC disassembly during mitotic entry. Cell. 2011;144(4):539–50.
doi: 10.1016/j.cell.2011.01.012 pubmed: 21335236
Xu H, Valerio DG, Eisold ME, et al. NUP98 fusion proteins interact with the NSL and MLL1 complexes to drive leukemogenesis. Cancer Cell. 2016;30(6):863–78.
doi: 10.1016/j.ccell.2016.10.019 pubmed: 27889185 pmcid: 5501282
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
ISCN 2020. An international system for human cytogenomic nomenclature (2020). S. Karger AG; 2020.
DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43(5):491–8.
doi: 10.1038/ng.806 pubmed: 21478889 pmcid: 3083463
Uhrig S, Ellermann J, Walther T, et al. Accurate and efficient detection of gene fusions from RNA sequencing data. Genome Res. 2021;31(3):448–60.
doi: 10.1101/gr.257246.119 pubmed: 33441414 pmcid: 7919457
Anders S, Pyl PT, Huber W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31(2):166–9.
doi: 10.1093/bioinformatics/btu638 pubmed: 25260700
Frankish A, Diekhans M, Jungreis I, et al. Gencode 2021. Nucleic Acids Res. 2021;49(D1):D916–23.
doi: 10.1093/nar/gkaa1087 pubmed: 33270111
Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating viruses and cellular organisms. Nucleic Acids Res. 2021;49(D1):D545–51.
doi: 10.1093/nar/gkaa970 pubmed: 33125081
Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32(18):2847–9.
doi: 10.1093/bioinformatics/btw313 pubmed: 27207943
Nakamura T, Largaespada DA, Lee MP, et al. Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia. Nat Genet. 1996;12(2):154–8.
doi: 10.1038/ng0296-154 pubmed: 8563753
Borrow J, Shearman AM, Stanton VP Jr, et al. The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9. Nat Genet. 1996;12(2):159–67.
doi: 10.1038/ng0296-159 pubmed: 8563754
Qiao Q, Li Y, Chen Z, Wang M, Reinberg D, Xu RM. The structure of NSD1 reveals an autoregulatory mechanism underlying histone H3K36 methylation. J Biol Chem. 2011;286(10):8361–8.
doi: 10.1074/jbc.M110.204115 pubmed: 21196496
van Zutven LJ, Onen E, Velthuizen SC, et al. Identification of NUP98 abnormalities in acute leukemia: JARID1A (12p13) as a new partner gene. Genes Chromosomes Cancer. 2006;45(5):437–46.
doi: 10.1002/gcc.20308 pubmed: 16419055
de Rooij JD, Masetti R, van den Heuvel-Eibrink MM, et al. Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study. Blood. 2016;127(26):3424–30.
doi: 10.1182/blood-2016-01-695551 pubmed: 27114462 pmcid: 5161011
Zhang J, Shen H, Song H, et al. A novel NUP98/RARG gene fusion in pediatric acute myeloid leukemia resembling acute promyelocytic leukemia. J Pediatr Hematol Oncol. 2022;44(3):e665–71.
doi: 10.1097/MPH.0000000000002331 pubmed: 35319505
Bertrums EJM, Smith JL, Harmon L, et al. Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia. Haematologica. 2023;108(8):2044–58.
doi: 10.3324/haematol.2022.281653 pubmed: 36815378 pmcid: 10388277
Wei W, Liu Q, Song F, et al. Alkaloid-based regimen is beneficial for acute myeloid leukemia resembling acute promyelocytic leukemia with NUP98/RARG fusion and RUNX1 mutation: a case report. Medicine. 2020;99(40): e22488.
doi: 10.1097/MD.0000000000022488 pubmed: 33019444 pmcid: 7535657
Shiba N, Ichikawa H, Taki T, et al. NUP98-NSD1 gene fusion and its related gene expression signature are strongly associated with a poor prognosis in pediatric acute myeloid leukemia. Genes Chromosomes Cancer. 2013;52(7):683–93.
doi: 10.1002/gcc.22064 pubmed: 23630019
Fasan A, Haferlach C, Alpermann T, Kern W, Haferlach T, Schnittger S. A rare but specific subset of adult AML patients can be defined by the cytogenetically cryptic NUP98-NSD1 fusion gene. Leukemia. 2013;27(1):245–8.
doi: 10.1038/leu.2012.230 pubmed: 22945772
Ostronoff F, Othus M, Gerbing RB, et al. NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. Blood. 2014;124(15):2400–7.
doi: 10.1182/blood-2014-04-570929 pubmed: 25145343 pmcid: 4192751
Wang GG, Cai L, Pasillas MP, Kamps MP. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol. 2007;9(7):804–12.
doi: 10.1038/ncb1608 pubmed: 17589499
Huang HW, Chen CY, Huang YH, et al. CMAHP promotes metastasis by reducing ubiquitination of Snail and inducing angiogenesis via GM-CSF overexpression in gastric cancer. Oncogene. 2022;41(2):159–72.
doi: 10.1038/s41388-021-02087-8 pubmed: 34716430
Hu X, Yang L, Mo YY. Role of pseudogenes in tumorigenesis. Cancers. 2018;10(8):256.
doi: 10.3390/cancers10080256 pubmed: 30071685 pmcid: 6115995
Jaatinen T, Hemmoranta H, Hautaniemi S, et al. Global gene expression profile of human cord blood-derived CD133+ cells. Stem Cells. 2006;24(3):631–41.
doi: 10.1634/stemcells.2005-0185 pubmed: 16210406
Tuborgh A, Meyer C, Marschalek R, Preiss B, Hasle H, Kjeldsen E. Complex three-way translocation involving MLL, ELL, RREB1, and CMAHP genes in an infant with acute myeloid leukemia and t(6;19;11)(p22.2;p13.1;q23.3). Cytogenet Genome Res. 2013;141(1):7–15.
doi: 10.1159/000351224 pubmed: 23735562
Robertson G, Schein J, Chiu R, et al. De novo assembly and analysis of RNA-seq data. Nat Methods. 2010;7(11):909–12.
doi: 10.1038/nmeth.1517 pubmed: 20935650
Shiba N, Ohki K, Kobayashi T, et al. High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: the results of the Japanese paediatric leukaemia/lymphoma study group AML-05 trial. Br J Haematol. 2016;172(4):581–91.
doi: 10.1111/bjh.13869 pubmed: 26684393
Heikamp EB, Henrich JA, Perner F, et al. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. Blood. 2022;139(6):894–906.
doi: 10.1182/blood.2021012806 pubmed: 34582559 pmcid: 8832476
Lewuillon C, Laguillaumie MO, Quesnel B, Idziorek T, Touil Y, Lemonnier L. Put in a “Ca(2+)ll” to acute myeloid leukemia. Cells. 2022;11(3):543.
doi: 10.3390/cells11030543 pubmed: 35159351 pmcid: 8834247

Auteurs

Jing-Ying Zhang (JY)

Division/Center of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, 310005, China.
The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, Hangzhou, 310005, China.
National Clinical Research Center for Child Health, Hangzhou, 310005, China.

Chun-Rong Chen (CR)

Division/Center of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, 310005, China.
The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, Hangzhou, 310005, China.
National Clinical Research Center for Child Health, Hangzhou, 310005, China.

Jia-Yue Qin (JY)

Department of Medical Affairs, Acornmed Biotechnology Co., Ltd., Beijing, 100176, China.

Di-Ying Shen (DY)

Division/Center of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, 310005, China.
The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, Hangzhou, 310005, China.
National Clinical Research Center for Child Health, Hangzhou, 310005, China.

Li-Xia Liu (LX)

Department of Medical Affairs, Acornmed Biotechnology Co., Ltd., Beijing, 100176, China.

Hua Song (H)

Division/Center of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, 310005, China.
The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, Hangzhou, 310005, China.
National Clinical Research Center for Child Health, Hangzhou, 310005, China.

Tian Xia (T)

Division/Center of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, 310005, China.
The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, Hangzhou, 310005, China.
National Clinical Research Center for Child Health, Hangzhou, 310005, China.

Wei-Qun Xu (WQ)

Division/Center of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, 310005, China.
The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, Hangzhou, 310005, China.
National Clinical Research Center for Child Health, Hangzhou, 310005, China.

Yan Wang (Y)

Division/Center of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, 310005, China.
The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, Hangzhou, 310005, China.
National Clinical Research Center for Child Health, Hangzhou, 310005, China.

Feng Zhu (F)

Division/Center of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, 310005, China.
The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, Hangzhou, 310005, China.
National Clinical Research Center for Child Health, Hangzhou, 310005, China.

Mei-Xin Fang (MX)

Division/Center of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, 310005, China.
The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, Hangzhou, 310005, China.
National Clinical Research Center for Child Health, Hangzhou, 310005, China.

He-Ping Shen (HP)

Division/Center of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, 310005, China.
The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, Hangzhou, 310005, China.
National Clinical Research Center for Child Health, Hangzhou, 310005, China.

Chan Liao (C)

Division/Center of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, 310005, China.
The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, Hangzhou, 310005, China.
National Clinical Research Center for Child Health, Hangzhou, 310005, China.

Ao Dong (A)

National Clinical Research Center for Child Health, Hangzhou, 310005, China.
Department of Clinical Laboratory, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, 310005, China.

Shan-Bo Cao (SB)

Department of Medical Affairs, Acornmed Biotechnology Co., Ltd., Beijing, 100176, China.

Yong-Min Tang (YM)

Division/Center of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, 310005, China.
The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, Hangzhou, 310005, China.
National Clinical Research Center for Child Health, Hangzhou, 310005, China.

Xiao-Jun Xu (XJ)

Division/Center of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, 310005, China. xuxiaojun@zju.edu.cn.
The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, Hangzhou, 310005, China. xuxiaojun@zju.edu.cn.
National Clinical Research Center for Child Health, Hangzhou, 310005, China. xuxiaojun@zju.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH